Casdin Capital 13F holdings, Q4 2019
Holdings as of December 31, 2019 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 31 US equity positions worth $1.1bn in its Q4 2019 13F filing. The largest position was SRPT at 8.0% of the reported book, followed by BLUEBIRD BIO INC and CDXS. Against the Q3 2019 filing, it opened 1 new position, added to 10 and reduced 8 among the top 31 holdings.
What did Casdin Capital own in Q4 2019? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2019 |
|---|---|---|---|---|---|---|---|
| 1 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 8.0% | $86.5m | 670,000 | -24% | reduced |
| 2 | BLUEBIRD BIO INC | 7.9% | $85.1m | 970,000 | 58% | added | |
| 3 | CDXS CODEXIS INC | Healthcare | 7.6% | $81.1m | 5,073,780 | 0% | held |
| 4 | 2655787D BLUEPRINT MEDICINES CORP | 7.0% | $75.3m | 940,000 | 0% | held | |
| 5 | MYOKARDIA INC | 6.8% | $73.2m | 1,005,000 | -10% | reduced | |
| 6 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 5.5% | $59.3m | 515,000 | -14% | reduced |
| 7 | INVITAE CORP | 5.5% | $58.7m | 3,638,388 | -5% | reduced | |
| 8 | CNST CONSTELLATION PHARMCETICLS I | 5.3% | $57.1m | 1,212,734 | -20% | reduced | |
| 9 | AUDENTES THERAPEUTICS INC | 4.8% | $51.5m | 860,000 | 0% | held | |
| 10 | FATE FATE THERAPEUTICS INC | Healthcare | 4.6% | $49.9m | 2,550,000 | 0% | held |
| 11 | MAGENTA THERAPEUTICS INC | 4.4% | $47.0m | 3,098,121 | 2% | added | |
| 12 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 3.7% | $39.9m | 2,468,571 | 2% | added |
| 13 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 3.7% | $39.4m | 825,000 | -12% | reduced |
| 14 | CDNA CAREDX INC | Healthcare | 2.4% | $25.9m | 1,200,000 | 20% | added |
| 15 | GLOBAL BLOOD THERAPEUTICS IN | 2.2% | $23.8m | 300,000 | 0% | held | |
| 16 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.0% | $21.8m | 1,250,000 | 92% | added |
| 17 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.9% | $20.6m | 1,239,285 | 47% | added |
| 18 | ILMN ILLUMINA INC | Healthcare | 1.9% | $19.9m | 60,000 | 0% | held |
| 19 | 2JQ GRITSTONE ONCOLOGY INC | 1.8% | $19.4m | 2,160,000 | 22% | added | |
| 20 | ALEC ALECTOR INC | Healthcare | 1.7% | $18.5m | 1,076,039 | 33% | added |
| 21 | SG7 SAGE THERAPEUTICS INC | 1.5% | $16.6m | 230,000 | -43% | reduced | |
| 22 | GNMK GENMARK DIAGNOSTICS INC | 1.5% | $16.2m | 3,365,000 | 0% | held | |
| 23 | DECIPHERA PHARMACEUTICALS IN | 1.5% | $15.9m | 255,000 | 155% | added | |
| 24 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 1.4% | $15.3m | 1,095,075 | -3% | reduced |
| 25 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 1.3% | $13.9m | 463,125 | 0% | held |
| 26 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 1.1% | $12.2m | 1,455,000 | 0% | held |
| 27 | ORCHARD THERAPEUTICS PLC | 1.0% | $11.3m | 820,000 | 165% | added | |
| 28 | TWST TWIST BIOSCIENCE CORP | Healthcare | 0.6% | $6.3m | 300,000 | 0% | held |
| 29 | TURNING POINT THERAPEUTICS I | 0.4% | $4.7m | 75,000 | 0% | held | |
| 30 | BRISTOL MYERS SQUIBB CO | 0.4% | $4.5m | 1,500,000 | – | new | |
| 31 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.3% | $3.7m | 130,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.